Development of novel human antibody against malignant glioma-derived stem cell
| Project/Area Number |
25430166
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Shizuoka Cancer Center Research Institute |
|---|
Principal Investigator |
Akiyama Yasuto 静岡県立静岡がんセンター(研究所), その他部局等, その他 (70222552)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 抗体医薬 / がん性幹細胞 / 悪性グリオーマ / ヒト化マウス / ヒトモノクローナル抗体 |
|---|
| Outline of Final Research Achievements |
We aimed with developing human monoclonal antibody against YKL-40 protein, which is specifically expressed on malignant glioma-derived stem cell line established at Shizuoka Cancer Center, using humanized NOG-IL-4 transgenic (TG) mice. After immunization of recombinant human YKL-40 protein to humanized NOG-IL-4 TG mice and verification of antibody titer elevation, 7 anti-YKL-40 antibody-bearing single B cells out of ten million oflymphocytes were identified and sebsequently 4 specific antibody cDNAs were successfully cloned. Finally, 3 human recombinat monoclonal antibodies against YKL-40 protein were obtained using expi293 cells transduced with antibody genes consisting of VH and VL gene. These antibodies have still weak binding affinity for YKL-40 protein, therefore affinity maturation process will be needed using a phage display system.
|
Report
(4 results)
Research Products
(15 results)
-
-
[Journal Article] Immunologically augmented skin flap as a novel dendritic cell vaccine against head and neck cancer in a rat model.2015
Author(s)
Inoue K, Saegusa N, Omiya M, Ashizawa T, Miyata H, Komiyama M, Iizuka A, Kume A, Sugino T, Yamaguchi K, Kiyohara Y, Nakagawa M, Akiyama Y.
-
Journal Title
Cancer Sci.
Volume: 106 (2)
Issue: 2
Pages: 143-150
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.2014
Author(s)
Akiyama Y, Ashizawa T, Komiyama M, Miyata H, Oshita C, Omiya M, Iizuka A, Kume A, Sugino T, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K.
-
Journal Title
Oncol Rep
Volume: 32 (1)
Issue: 1
Pages: 159-166
DOI
Related Report
Peer Reviewed
-
[Journal Article] Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line2014
Author(s)
Ashizawa T, Akiyama Y, Miyata H, Iizuka A, Komiyama M, Kume A, Omiya M, Sugino T, Asai A, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K
-
Journal Title
Int J Oncol.
Volume: 411-8
Issue: 1
Pages: 411-418
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
